Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 935-944

  Tamatani, Tetsuya ^a   Takamaru, Natsumi ^a   Hara, Kanae ^a   Kinouchi, Makoto ^a   Kuribayashi, Nobuyuki ^a   Ohe, Go ^a   Uchida, Daisuke ^a   Fujisawa, Kenji ^a   Nagai, Hirokazu ^a   Miyamoto, Youji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bortezomib; Nuclear factor B; Oral cancer

Indexed keywords

BORTEZOMIB; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIATION EXPOSURE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-6; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PYRAZINES; RADIATION-SENSITIZING AGENTS; TRANSCRIPTION FACTOR RELA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873618659     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1786     Document Type: Article

References (54)

1. Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986. (Pubitemid 16020062)
2. Baeuerle PA and Baltimore D: NF-kappa B: ten years after. Cell 87: 13-20, 1996.
3. Yamamoto Y and Gaynor RB: IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci 29: 72-79, 2004. (Pubitemid 38186577)
4. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
5. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA: Phosphorylation of human IkappaB-alpha on serines 32 and 36 controls Ikappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14: 2876-2883, 1995.
6. Karashima T, Sweeney P, Kamat A, et al: Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through regulation of interleukin-8. Clin Cancer Res 9: 2786-2797, 2003. (Pubitemid 36842125)
7. Dhawan P, Singh AB, Ellis DL and Richmond A: Constitutive activation of Akt/Protein kinase B in melanoma leads to up regulation of nuclear factor-κB and tumor progression. Cancer Res 62: 7335-7342, 2002. (Pubitemid 36025257)
8. Sato H and Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405, 1993. (Pubitemid 23073756)
9. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase 8 activation. Science 281: 1680-1683, 1998.
10. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5: 412-417, 1999. (Pubitemid 29180579)
11. Hideshima T, Chauhan D, Richardson P, et al: NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002. (Pubitemid 34967682)
12. Denlinger CE, Rundall BK and Jones DR: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. Semin Thorac Cardiovasc Surg 16: 28-39, 2004. (Pubitemid 38714757)
13. Smith CW, Chen Z, Dong G, et al: The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1a, IL-6, GM-CSF and KC. Clin Exp Metastasis 16: 655-664, 1998. (Pubitemid 29044588)
14. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T and Sato M: Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett 171: 165-172, 2001. (Pubitemid 32772803)
15. Tamatani T, Azuma M, Ashida Y, et al: Enhanced radiosensitization and chemosensitization in NF-κB suppressed human oral cancer cells via the inhibition of γ-irradiation- and 5 FU induced production of IL-6 and IL-8. Int J Cancer 108: 912-921, 2004. (Pubitemid 38112622)
16. Visconti R, Cerutti J, Battista S, et al: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression. Oncogene 15: 1987-1994, 1997.
17. Sartore-Bianchi FA, Gasparri F, Galvani A, et al: Bortezomib inhibits nuclear factor-κB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942-5951, 2007. (Pubitemid 47583922)
18. Canfield SE, Zhu K, Williams SA and McConkey DJ: Bortezomib inhibits docetaxel-induced apoptosis via a p21 dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5: 2043-2050, 2006. (Pubitemid 44336576)
19. Bazzaro M, Lee MK, Zoso A, et al: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor induced apoptosis. Cancer Res 66: 3754-3763, 2006.
20. An J, Sun YP, Adams J, Fisher M, Belldegrun A and Rettig MB: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) a and TNF related apoptosis inducing ligand in prostate cancer. Clin Cancer Res 9: 4537-4545, 2003. (Pubitemid 37248413)
21. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498, 2005. (Pubitemid 41507710)
22. Olivier S, Robe P and Bours V: Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72: 1054-1068, 2006. (Pubitemid 44465845)
23. Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C and Krönke M: NF-κB independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 109: 3982-3988, 2007. (Pubitemid 46641751)
24. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999. (Pubitemid 29269108)
25. Duffey DC, Chen Z, Dong G, et al: Expression of a dominant negative mutant inhibitor-κBa of nuclear factor κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 59: 3468-3474, 1999. (Pubitemid 29334510)
26. Tomita T, Takeuchi E, Tomita N, et al: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42: 2532-2542, 1999. (Pubitemid 30327169)
27. Kim IA, Bae SS, Fernandes A, et al: Selective inhibition of Ras, phosphoinositide 3 kinase and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65: 7902-7910, 2005. (Pubitemid 41297268)
28. Matsumoto G, Namekawa J, Muta M, et al: Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11: 1287-1293, 2005. (Pubitemid 40175782)
29. Messersmith WA, Baker SD, Lassiter L, et al: Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12: 1270-1275, 2006. (Pubitemid 43342518)
30. Cataldi A, Rapino M, Centurione L, et al: NF-κB activation plays an antiapoptotic role in human leukemic K562 cells exposed to ionizing radiation. J Cell Biochem 89: 956-963, 2003. (Pubitemid 36927727)
31. Loercher A, Lee TL, Ricker JL, et al: Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64: 6511-6523, 2004. (Pubitemid 39297908)
32. Van Waes C, Chang AA, Lebowitz PF, et al: Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412, 2005. (Pubitemid 41628035)
33. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930, 2003. (Pubitemid 36827209)
34. Tan C and Waldmann TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62: 1083-1086, 2002. (Pubitemid 34160291)
35. Scaife CL, Kuang J, Wills JC, et al: Nuclear factor κB inhibitors induce adhesion dependent colon cancer apoptosis: implications for metastasis. Cancer Res 62: 6870-6878, 2002. (Pubitemid 35424075)
36. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002. (Pubitemid 34984425)
37. Amiri KI, Horton LW, LaFleur BJ, Sosman JA and Richmond A: Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS 341) as a therapeutic agent for malignant melanoma. Cancer Res 64: 4912-4918, 2004. (Pubitemid 38924537)
38. Rahman KM and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB contributes to 3, 3'-diindolylmethane induced apoptosis in breast cancer cells. Cancer Res 65: 364-371, 2005. (Pubitemid 40070830)
39. Huang S, Robinson JB, Deguzman A, et al: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339, 2000.
40. Arlt A, Vorndamm J, Müerköster S, et al: Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62: 910-916, 2002. (Pubitemid 34126972)
41. Yang J and Richmond A: Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res 61: 4901-4909, 2001. (Pubitemid 32691908)
42. Kothny-Wilkes G, Kulms D, Luger TA, et al: Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis. J Biol Chem 274: 28916-28921, 1999.
43. Vale T, Ngo TT, White MA and Lipsky PE: Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Res 61: 602-607, 2001. (Pubitemid 32128621)
44. Huang TT, Wuerzberqer-Davis SM, Wu ZH, et al: Sequential modification of NEMO/IKKγ by SUMO 1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115: 565-576, 2003. (Pubitemid 37506045)
45. Mabb AM, Wuerzberqer-Davis SM and Miyamoto S: PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress. Nat Cell Biol 8: 986-993, 2006. (Pubitemid 44314730)
46. Janssens S and Tschopp J: Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ 13: 773-784, 2006.
47. Munshi A, Kurland JF, Nishikawa T, et al: Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells. Mol Cancer Ther 3: 985-992, 2004. (Pubitemid 39199593)
48. Shumway SD and Miyamoto S: A mechanistic insight into a proteasome-independent constitutive inhibitor κBα (IκBα) degradation and nuclear factor κB (NF-κB) activation pathway in WEHI-231 B-cells. Biochem J 380: 173-180, 2004. (Pubitemid 38725742)
49. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378, 1999. (Pubitemid 29334495)
50. De Larco JE, Wuertz BR, Manivel JC and Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 61: 2857-2861, 2001. (Pubitemid 32691925)
51. Conze D, Weiss L, Regen PS, et al: Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858, 2001. (Pubitemid 34013900)
52. Tang G, Minemoto Y, Dibling B, et al: Inhibition of JNK activation through NF-κB target genes. Nature 414: 313-317, 2001. (Pubitemid 33097808)
53. Yu C, Friday BB, Lai JP, Yang L, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c Jun NH2 terminal kinase pathways. Mol Cancer Ther 5: 2378-2387, 2006. (Pubitemid 44530475)
54. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G and Wolf D: Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 361: 549-554, 2007. (Pubitemid 47187282)